ENOB Enochian Biosciences Inc

CUSIP No. 29350E104

_____________________________

¹ William Anderson Wittekind (“Wittekind”) has sole voting and sole dispositive power over such shares by virtue of his status as sole manager of Weird Science LLC (“Weird Science”) as of the date of the event reported herein.

² Based upon 52,798,267 shares of common stock outstanding as of March 31, 2022 as disclosed in the issuer’s Form 10-Q filed with the Commission on May 15, 2022. Weird Science ceased to own more than 5% of the issuer’s Common Stock on the date of the event reported herein.

CUSIP No. 29350E104

_____________________________

³ Consists of (a) 3,615,757 shares owned by Wittekind; (b) 97,032 shares owned by Weird Science; (c) 633,921 shares owned by the William Anderson Wittekind 2020 Annuity Trust, a grantor retained annuity trust of which Wittekind is the sole trustee (the “Wittekind 2020 Annuity Trust”); (d) 450,568 shares owned by the Dybul 2020 Angel Annuity Trust, a grantor retained annuity trust of which Wittekind is the sole trustee (the “Dybul 2020 Annuity Trust”); (e) 50,000 shares owned by the Ty Mabry 2021 Annuity Trust, a grantor retained annuity trust of which Wittekind is sole trustee (the “Mabry 2021 Annuity Trust”); and (f) 366,079 shares owned by the William Anderson Wittekind 2021 Annuity Trust, a grantor retained annuity trust of which Wittekind is the sole trustee (the “Wittekind 2021 Annuity Trust” and, together with the Wittekind 2020 Annuity Trust, the Dybul 2020 Annuity Trust and the Mabry 2021 Annuity Trust, the “Trusts”). In his capacity as the sole manager of Weird Science, Wittekind has sole voting and sole dispositive power over the shares owned by Weird Science. In his capacity as the sole trustee, Wittekind has sole voting power and sole dispositive power over the shares owned by the Trusts.

⁴ Consists of 88,121 shares owned by Wittekind and Serhat Gumrukcu, Wittekind’s spouse (“Gumrukcu”), as joint tenants with a right of survivorship (“JTWROS”). Wittekind and Gumrukcu share the power vote and the power to dispose of the shares owned as JTWROS by virtue of their status as joint tenants. Excludes 12,439,371 shares owned by Gumrukcu, Wittekind’s spouse, of which Wittekind disclaims beneficial ownership pursuant to Rule 13d-4 (17 CFR 240.13d-4).

⁵ Based upon 52,798,267 shares of common stock outstanding as of March 31, 2022 as disclosed in the issuer’s Form 10-Q filed with the Commission on May 15, 2022.

EXPLANATORY NOTE

This Amendment No. 9 amends the Schedule 13D filed by Weird Science LLC, a California limited liability company (“Weird Science”) and William Anderson Wittekind, a member and manager of Weird Science (“Wittekind” and, together with Weird Science, the “Reporting Persons”), with respect to the shares of common stock, par value $0.0001 per share (“Common Stock”) of Enochian Biosciences Inc. (the “Issuer”) received by Weird Science pursuant to that certain Agreement and Plan of Merger dated January 12, 2018 (the “Merger Agreement”) by and among the Issuer (then known as DanDrit BioTech USA, Inc.), DanDrit Acquisition Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of the Issuer (“Merger Sub”), Enochian Biopharma, Inc., a Delaware corporation (“Target”), and Weird Science, in its capacity as the majority stockholder of the Target, as amended by Amendment No. 1, Amendment No. 2, Amendment 3, Amendment No. 4, Amendment No. 5, Amendment No. 6, Amendment No. 7 and Amendment No. 8 thereto.

Capitalized terms used but not defined in this Amendment No. 9 have the meanings given to such terms in the initial Schedule 13D, as amended by Amendment No. 1, Amendment No. 2, Amendment No. 3, Amendment No. 4, Amendment No. 5, Amendment No. 6, Amendment No. 7 and Amendment No. 8 thereto.

Sandler resigned as a director of the Issuer and as a manager of Weird Science on March 25, 2022.

Weird Science ceased to beneficially own more than 5% of the Issuer’s outstanding Common Stock on April 15, 2022. See Item 5. Interests in Securities of the Issuer. As a result, upon the filing of this Amendment No. 9, Weird Science is no longer a Reporting Person under this Schedule 13D.

(a)-(c) On February 23, 2022 Sandler filed a Form 4 with the Commission reporting the sale of 6,972 shares of Common Stock at a price of $9.03 per share on February 18, 2022 and 6 shares of Common Stock at a price of $9 per share on February 23, 2022. On March 24, 2022 Sander filed a Form 4 with the Commission reporting the sale of 1,927 shares of Common Stock at a price of $9.06 per share. Sandler resigned as a director of the Issuer and as a manager of Weird Science on March 25, 2022. On or about February 14, 2022, Gumrukcu privately transferred 400 shares of Common Stock. On or about April 11, 2022, Weird Science received 97,032 shares of Common Stock as Earnout Stock pursuant to the Merger Agreement. On or about April 15, 2022, Weird Science distributed 4,961,363 shares of Common Stock to its members on a pro rata basis, consisting of 992,273 shares of Common Stock to Wittekind, 992,273 shares of Common Stock to Sandler and 2,976,817 shares of Common Stock to Gumrukcu.

Based upon the Issuer’s disclosure of 52,798,267 shares of Common Stock outstanding as of March 31, 2022, as disclosed by the Issuer in its Form 10-Q filed with the Commission on May 15, 2022, after giving effect to the foregoing:

(d)       Not applicable.

(e)       As stated above, Weird Science ceased to beneficially own more than 5% of the Issuer’s issued and outstanding Common Stock on or about April 15, 2022. As a result, upon the filing of this Amendment No. 9 Weird Science will cease to be a Reporting Person hereunder.

* The Joint Filing Agreement will terminate upon the filing of this Amendment No. 9.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this Amendment No. 9 is true, complete and correct.

Date: May 19, 2023

7